Trade Jazz Pharmaceuticals plc - JAZZ CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.49 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 121.96 |
| Open | 123.09 |
| 1-Year Change | 1.38% |
| Day's Range | 123.04 - 125.49 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | 121.96 | -1.08 | -0.88% | 123.04 | 124.35 | 121.40 |
| Dec 16, 2024 | 125.16 | 2.61 | 2.13% | 122.55 | 125.91 | 122.08 |
| Dec 13, 2024 | 122.54 | -0.05 | -0.04% | 122.59 | 123.38 | 120.82 |
| Dec 12, 2024 | 123.11 | -0.41 | -0.33% | 123.52 | 126.94 | 122.41 |
| Dec 11, 2024 | 120.62 | 0.55 | 0.46% | 120.07 | 120.95 | 117.65 |
| Dec 10, 2024 | 119.94 | -0.14 | -0.12% | 120.08 | 121.97 | 118.59 |
| Dec 9, 2024 | 120.69 | -1.42 | -1.16% | 122.11 | 123.58 | 120.31 |
| Dec 6, 2024 | 122.53 | -0.84 | -0.68% | 123.37 | 123.86 | 121.84 |
| Dec 5, 2024 | 123.06 | 0.47 | 0.38% | 122.59 | 123.55 | 120.10 |
| Dec 4, 2024 | 122.90 | 1.37 | 1.13% | 121.53 | 123.36 | 119.91 |
| Dec 3, 2024 | 121.48 | -0.25 | -0.21% | 121.73 | 122.75 | 120.48 |
| Dec 2, 2024 | 121.26 | 0.36 | 0.30% | 120.90 | 122.44 | 120.16 |
| Nov 29, 2024 | 121.18 | -1.52 | -1.24% | 122.70 | 122.70 | 120.64 |
| Nov 27, 2024 | 122.52 | 0.09 | 0.07% | 122.43 | 123.81 | 121.56 |
| Nov 26, 2024 | 122.75 | -0.60 | -0.49% | 123.35 | 123.35 | 120.13 |
| Nov 25, 2024 | 123.89 | -2.76 | -2.18% | 126.65 | 127.97 | 122.66 |
| Nov 22, 2024 | 126.12 | 2.20 | 1.78% | 123.92 | 127.42 | 123.92 |
| Nov 21, 2024 | 124.97 | 4.53 | 3.76% | 120.44 | 125.47 | 119.46 |
| Nov 20, 2024 | 119.25 | 3.89 | 3.37% | 115.36 | 119.36 | 115.36 |
| Nov 19, 2024 | 116.43 | -0.58 | -0.50% | 117.01 | 118.16 | 115.25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Jazz Pharma Company profile
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Jazz Pharmaceuticals PLC revenues increased 31% to $3.09B. Net loss totaled $329.7M vs. income of $238.6M. Revenues reflect Sunosi segment increase from $28.3M to $2.34B, Zepzelca segment increase from $90.4M to $246.8M, United States segment increase of 32% to $2.82B, Europe segment increase of 31% to $230.2M. Net loss reflects Selling.
Equity composition
Common Stock $.0001 Par, 4/11, 150M auth., 40,741,809 issd. Insiders & stakeholders own 2.30%. IPO 6/1/07, 6M shares @ $18 per share by Morgan Stanley & Co. Incorporated, Lehman Brothers Inc. 5/07 Reverse stock split 1 for 11.06701. PO: 7/08, 3.8M shares.
| Industry: | Pharmaceuticals (NEC) |
Fifth Fl
Waterloo Exchange
DUBLIN
DUBLIN 4
IE
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com